It should be a given fact for an industry so important to the world as pharmaceutical, but it’s still reassuring to see it announced publicly.

The European Medicines Agency (EMA) has this week reaffirmed that it will continue its long-standing commitment to independence and transparency in its evaluation of COVID-19 treatments and vaccines, as it does for all other medicines.

In an open letter to the European Ombudsman, Emily O’Reilly, it explains that since the start of the pandemic it “has been working with EU National Competent Authorities and the European Commission to harness expertise from across the EU”.

Among the exceptional measures being taken by the EMA, one notable step is compressing a multi-year process into a mere several months, by fully mobilizing resources to expedite their advice & evaluation processes. All while maintaining their safety and efficacy standards, and applying tested independence and transparency rules.

With potential new vaccines making front-page news almost daily, it’s reassuring to hear that tried and tested measures are being used to ensure that the EMA’s recommendations are driven only by science and public health needs, and not by any other interests.

Follow us on LinkedIn for more industry news and opinions.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency